iRhythm COO steps down amid 'business transformation' - FierceBiotech
FDA agrees to give Ipsen's rare disease drug another look as ... - FierceBiotech
Postpartum Depression Market to Witness Upsurge in Growth ... - Digital Journal
Acute Respiratory Distress Syndrome Pipeline Analysis ... - Digital Journal
UPDATE: Merck's TIGIT fails in phase 2 Keytruda combo, notching ... - FierceBiotech
Pregnant Women With Severe Mental Illness Benefit From ... - MD Magazine
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges - Yahoo Finance
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges - Nasdaq
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges - Zacks Investment Research
Form 8-K Sage Therapeutics, Inc. For: Mar 15 - StreetInsider.com

Pages